Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy

Area of Science:

• Medical Research
• Pulmonology
• Pharmacology

Background:

• Recent advancements in highly effective modulator therapy have improved health for individuals with cystic fibrosis (CF).
• An increasing number of people with CF are considering pregnancy due to improved health outcomes.
• The safety profile of highly effective modulator therapy during pregnancy and its effects on fetal development are not well-established.

Purpose of the Study:

• To review the current understanding of highly effective modulator therapy use in pregnant individuals with CF.
• To identify potential risks and knowledge gaps regarding maternal and fetal outcomes.
• To emphasize the importance of multidisciplinary counseling for reproductive-aged individuals with CF.

Main Methods:

• Literature review of existing studies on highly effective modulator therapy and pregnancy.
• Analysis of data regarding maternal health, fetal outcomes, and offspring development.
• Identification of areas requiring further prospective research.

Main Results:

• Limited data suggest potential risks, including a decline in maternal health upon therapy withdrawal and a possible association with offspring cataracts.
• Highly effective modulator therapy may impact newborn screening results and fetal outcomes due to transplacental passage.
• Current evidence is insufficient to fully ascertain safety during pregnancy.

Conclusions:

• Multidisciplinary counseling is crucial for reproductive-aged individuals with CF considering pregnancy.
• Further prospective studies are needed to fully evaluate the safety and impact of highly effective modulator therapy in pregnant CF patients and their offspring.
• Managing CF during pregnancy requires careful consideration of therapeutic benefits versus potential risks.